CJC-1295 With DAC vs Without DAC — What Those Three Letters Change

Both Start as the Same Molecule

Your body makes growth hormone releasing hormone — GHRH — a chain of 44 amino acids produced in the hypothalamus. Its job is to travel a very short distance to the pituitary and ask it to release growth hormone.

Researchers established early that only the first 29 amino acids are needed to do that. The remaining 15 could be discarded with no loss of effect. That shortened fragment, GRF(1-29), is the starting point for both versions on this page.

It has one serious flaw: it is destroyed almost immediately. An enzyme called DPP-4 patrols the bloodstream clipping the ends off exactly this kind of peptide, and natural GHRH survives only minutes. So four amino acids in the fragment were swapped for substitutes the enzyme cannot grip. That modified fragment is CJC-1295 without DAC, also sold as Mod GRF 1-29.

It survives roughly thirty minutes rather than a few. Useful, but still brief — and it is that brevity the DAC version was built to solve.

What DAC Actually Is

DAC stands for Drug Affinity Complex, which sounds proprietary and describes something quite simple: a small chemical hook bolted onto the end of the peptide.

The hook is designed to grab one particular thing — albumin, the most abundant protein in blood. Albumin is large, it is everywhere, and crucially it is long-lived: a single albumin molecule circulates for around twenty days before being cleared.

Picture a small parcel and a slow cargo ship. On its own the parcel sits on the dock and is cleared away by the end of the shift. Chained to a ship that will be at sea for three weeks, the same parcel is still in circulation long after it would otherwise have gone. Nothing about the parcel changed — its address, its contents, what it does when opened. Only how long it remains available.

That is the whole of DAC. It does not make the peptide stronger, does not change which receptor it acts on, and does not alter the instruction it carries. It changes duration, and duration alone — from about thirty minutes to roughly six to eight days.

Why Duration Changes More Than Convenience

A three-hundred-fold difference in duration sounds like a scheduling matter. It is not, because of how the system being signalled actually behaves.

Growth hormone is not released steadily. It comes in bursts — a series of pulses across the day, the largest during deep sleep, with quiet periods between them. Those quiet periods are not gaps in the system; they are part of how it works. Between bursts, receptors reset and the opposing signal — somatostatin, which tells the pituitary to stop — does its half of the job.

This is the doorbell again. A short-acting peptide presses the bell: someone comes, something happens, and then the bell stops and the household returns to normal. A long-acting one keeps the bell sounding. Both are recognisable signals — but they are different signals, and how a household responds to a continuous one is a separate question from how it responds to a press.

The general principle behind that question is well established across endocrinology: systems built around intermittent signals often respond differently, and sometimes less, when the signal becomes constant. Receptors reduce in number under sustained stimulation. It is the same logic explored in gonadorelin and the GnRH system, where the effect is dramatic enough that continuous and pulsatile delivery of the identical molecule produce opposite outcomes.

The Finding That Complicates This

Everything above builds towards a tidy conclusion: pulses are natural, continuous elevation replaces that rhythm, therefore the short-acting version is the more faithful one. It is a satisfying argument, and it is worth checking against what was actually measured before accepting it.

The research does not fully support it. When Ionescu and Frohman examined what actually happened to growth hormone secretion during continuous stimulation with CJC-1295 with DAC, they found that pulsatility persisted. Mean GH levels rose, but the pulses did not flatten into a plateau — the underlying rhythm continued underneath the raised baseline.

The picture is closer to tide and waves than to a bell being jammed. Raising the tide does not stop waves forming; they arrive on top of a higher sea level. The pituitary appears to hold its own rhythm rather than surrendering it to the incoming signal — which is a more interesting result than the neat story, and a reminder that biological systems are frequently more robust than a mechanism diagram suggests.

What remains genuinely open is the longer-term picture. Persistent pulsatility over the days of a study does not establish what sustained elevation of both GH and IGF-1 does over months, and the trial evidence in that direction is limited. So the honest position is not "continuous is worse" — it is that the two versions produce different signal shapes, that the short-acting one more closely resembles the body's own pattern, and that whether resemblance translates into a better outcome has not been settled.

How the Two Actually Differ

Pulling the mechanics together, the difference between the two versions comes down to one thing and its consequences.

The short-acting version produces a signal that ends. Whatever it does, it stops within about half an hour and nothing remains in circulation. The DAC version produces one that persists for days. Both act at the same receptor with the same potency and carry the same instruction — the difference is entirely in how long the instruction stays on the table.

Neither shape is established as the better one. A brief signal more closely resembles the body's own pattern; a sustained one maintains elevated levels without repeat administration. The research does not settle which of those matters more, and the Ionescu and Frohman finding above shows the pituitary is less easily overridden than the simple argument assumes. Which version suits a given research question depends entirely on what that question is.

The science behind DAC is sound and solves a genuine problem elegantly; the short-acting version stays closer to the body's own pattern. Those are descriptions of two designs, not a ranking of them.

For how this compound sits against the other secretagogues, see CJC-1295 vs Ipamorelin vs Tesamorelin, and growth hormone secretagogues explained for the two pathways involved.

Frequently Asked Questions

Published References

1. Teichman SL, Neale A, Lawrence B, et al. “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.” The Journal of clinical endocrinology and metabolism, 2006. PubMed
2. Ionescu M, Frohman LA. “Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.” The Journal of clinical endocrinology and metabolism, 2006. PubMed
3. Jetté L, Léger R, Thibaudeau K, et al. “Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.” Endocrinology, 2005. PubMed

Browse all CJC-1295: With DAC vs Without research on PubMed →